Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

  • 00:28

    Exclusive Ideagen Ideas Leader Interview with Anthony Magnetti - Sunovion

    in News

    Anthony J. Magnetti


    Sunovion Pharmaceuticals Inc.


    Anthony Magnetti is a seasoned pharmaceutical executive with more than 40 years of experience that spans Government Affairs, Medical Affairs, Clinical Research Services, and Sales and Marketing.


    Currently, Mr. Magnetti leads Government Affairs for Sunovion Pharmaceuticals Inc., which focuses on therapies that advance the science of medicine in the psychiatry, neurology and respiratory disease areas to improve the lives of patients and their families.


    In this role Mr. Magnetti is responsible for addressing public policy and regulatory areas important to the company’s therapeutic areas of focus and the patients it serves. He has led several initiatives focused on preserving and expanding access to medicines and services that patients need. Over the last five years, Mr. Magnetti has helped enable the introduction and passage of numerous pieces of legislation putting patient protections into law, and has guided efforts to codify the six protected classes in Medicare Part D. Under his leadership, the Government Affairs team supports leading advocacy, educational, and cross-sector coalitions focused on the advancement of research and innovation, as well as improvements in healthcare.


    Mr. Magnetti joined the company in 1997 and in addition to Government Affairs has held increasingly senior roles across various functions including building and leading the Respiratory and Central Nervous System Medical Liaison Teams for Sunovion. 


    Mr. Magnetti holds a Bachelor’s degree in Biology from the State University of New York Albany. He serves on executive committees at Sunovion, as well as on several committees of biopharmaceutical industry organizations. 

  • 01:03

    Violet ReikiRadio -By Popular Demand-Dr. Sheldon Marc Feldman's interview

    in Health

    Dr. Sheldon Feldman is chief of breast surgery at NewYork-Presbyterian Hospital/Columbia University Medical Center and assistant professor of surgery at Columbia University College of Physicians and Surgeons where he oversees the breast cancer surgery program at the Comprehensive Breast Center of the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia, and work in close collaboration with a multidisciplinary team of radiologists, medical oncologists, radiation oncologists, plastic surgeons and other breast cancer support staff.


    Dr. Feldman is helping to pioneer the use of the ductoscope, a tiny endoscope inserted through the patient's nipple used for diagnosis, surveillance and treatment of cancer patients. His research using the device may help lead to a simple test for early diagnosis that could eventually be the equivalent of a Pap smear for breast cancer. Dr. Feldman anticipates that the intraductal approach will ultimately be used to treat early breast cancer as well as ablating the milk ducts to prevent cancer development for high-risk women as an alternative to mastectomy.


    A leader in minimally invasive breast cancer surgery, Dr. Feldman was instrumental in developing the transmammary axillary lymph node evaluation (TANE) procedure, which requires only a single incision for lumpectomy and sentinel lymph node biopsy. He is also an expert in oncoplastic skin-sparing and nipple-preserving mastectomy.


    His research interests are focused on preventing the disease through a better understanding of environmental toxins linked to breast cancer, including chlorinated pesticides, PCBs and PBDEs, and he is helping to investigate new biopharmaceutical treatments, including green tea extract and vitamin D.

  • 01:01

    Violet ReikiRadio - Guest Sheldon Marc Feldman M.D. FACS,

    in Health

    Dr. Sheldon Feldman is chief of breast surgery at NewYork-Presbyterian Hospital/Columbia University Medical Center and assistant professor of surgery at Columbia University College of Physicians and Surgeons where he oversees the breast cancer surgery program at the Comprehensive Breast Center of the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia, and work in close collaboration with a multidisciplinary team of radiologists, medical oncologists, radiation oncologists, plastic surgeons and other breast cancer support staff.


    Dr. Feldman is helping to pioneer the use of the ductoscope, a tiny endoscope inserted through the patient's nipple used for diagnosis, surveillance and treatment of cancer patients. His research using the device may help lead to a simple test for early diagnosis that could eventually be the equivalent of a Pap smear for breast cancer. Dr. Feldman anticipates that the intraductal approach will ultimately be used to treat early breast cancer as well as ablating the milk ducts to prevent cancer development for high-risk women as an alternative to mastectomy.


    A leader in minimally invasive breast cancer surgery, Dr. Feldman was instrumental in developing the transmammary axillary lymph node evaluation (TANE) procedure, which requires only a single incision for lumpectomy and sentinel lymph node biopsy. He is also an expert in oncoplastic skin-sparing and nipple-preserving mastectomy.


    His research interests are focused on preventing the disease through a better understanding of environmental toxins linked to breast cancer, including chlorinated pesticides, PCBs and PBDEs, and he is helping to investigate new biopharmaceutical treatments, including green tea extract and vitamin D.

  • 00:46

    A special talk with Survivors of Domestic Violence

    in Writing

    Thursday Carla Wynn Hall will be speaking with Makia Baker, Valerie Gregory, and Sharon Tam, three co-authors who have survived domestic violence and write their stories in Empowered Women of Social Media. 


    Sharon Tam


    Sharon Tam is a healthcare professional who loves to learn from manufacturing and testing biopharmaceutical drugs to clinical practice, therapy, healing, health, and wellness...more


    Valerie Gregory, AKA “The Warrior”


    Valerie is a single mom who works for one of the top investment firms in the country. She is a loving mother to a beautiful little girl. She is also a domestic violence survivor. She is now using her voice to speak out against this horrific epidemic. In sharing her story, she hopes that it will give others courage to break their silence...more


    Makia Baker


    Today I am an independent consultant for Jamberry Nails which has given me the opportunity to polish my sales skills. People skills are easy for me because I was able to develop them after years of being in abusive relationships. My friends say I am dependable and kind. I love my family and would do anything in the world for them. This is my first writing experience and I am totally loving it...more


    Visit Our Website 


    About our Sponsors


     

  • 00:07

    How ELNs can help maximise biopharmaceutical lab efficiency

    in Business

    Learn firsthand about deployment of ELNs within the biopharmaceutical area - this interview with Ralph Haffner, head of biologic research informatics at Roche, documents the drivers, the planning and selection phase, through to the deployment and integration. He also comments on how the industry is moving forward on creating an IT architecture and offers his views on the potential integration of the iPad to support an ELN system.

  • 00:31

    THE NATIONAL PHARMACEUTICAL COUNCIL

    in Business

    The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.


    Founded in 1953 and supported by the nation’s major research-based biopharmaceutical companies, NPC focuses on research development, information dissemination, education and communication of the critical issues of evidence, innovation and the value of medicines for patients. The issues we select for examination and the researchers and academics we partner with position NPC as a uniquely credible and trusted voice in the biopharmaceutical research and health policy communities. Much of our research is published in peer-reviewed journals.


    NPC is working to:



    Ensure that sound evidence is recognized by independent experts, considered appropriately by private and public payers, reflected adequately in benefit designs, and incorporated into clinical practice
    Demonstrate and promote the contribution of innovative medicines to optimizing health and wellness for patients and the entire health care system through scientific analyses and fact-based communications
    Maintain a focus on the issues related to advancing the science and research aspects of the biopharmaceutical industry and preserving and improving an environment supportive of innovation.


    Our Board of Directors consists of a representative from each member company. The annual dues paid by our members make up NPC’s core budget, which funds research-based projects, ongoing educational activities and our day-to-day operations. NPC does not engage in lobbying activities.

  • 00:31

    Pharmacy Podcast Episode 156 NATIONAL PHARMACEUTICAL COUNCIL

    in Business



    THE NATIONAL PHARMACEUTICAL COUNCIL


     





    The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
    Founded in 1953 and supported by the nation’s major research-based biopharmaceutical companies, NPC focuses on research development, information dissemination, education and communi

  • 00:26

    Pharmacy Podcast Episode 77 Interview with Drug Channel's Adam J. Fein, Ph.D.

    in Business


    ADAM J. FEIN, PH.D.
    Drug Channels was created and is written by Adam J. Fein, Ph.D., one of the country’s foremost experts on pharmaceutical economics and channel strategy. The president of Pembroke Consulting, Inc., and CEO of Drug Channels Institute, Dr. Fein consults with clients in the pharmaceutical and healthcare industries. Eleven of the 15 largest biopharmaceutical manufacturers have relied upon Dr. Fein for his experience, analyses, and insights to help them improve profitability and make better strategic decisions.

    Dr. Fein excels at unlocking and explaining complex business and economic issues with humor and an accessible, straightforward style, making Drug Channels a popular and authoritative destination for both industry insiders and outsiders. 

  • 00:25

    Delving Deeper Into Drug Risks

    in Business

    A conversation with John J. Doyle, Sr. Vice President and Managing Director - Global Market Access at Quintiles, about the need for deeper knowledge of the inherent risks of pharmaceutical products.
    This need was revealed by The New Health Report 2012, which is based on surveys of biopharmaceutical executives, managed care executives in the U.S., National Health Service executives in the U.K., patients living with chronic disease in both the U.S. and the U.K., and investors who focus on the healthcare sectors.

  • 01:29

    ALS Updates on Research and Exciting Clinical Trials

    in Culture

     
    Please join me on Wednesday evening, March 7th at 5 PM PST on "The Global Voice". This week's show will be dedicated to some exciting ALS breakthroughs in research and clinical trials , a registry that many PALS may not be aware of and an opportunity to call in and ask your questions about what's happening and how you can get involved.  Please call in to the show at 347-884-8988 and please stay on the switchboard for your call to be received. Our guests will be Mike Shannon of ALS TDI, Michele Dupre of PALS, spokesperson and blogger extraordinaire for ALS, Eric N. Valor and ANDREW GENGOS (pronounced JenJoss)Andrew is President, CEO and a Board Member of Neuraltus Pharmaceuticals, a private stage biopharmaceutical company dedicated to developing therapeutics to treat neurodegenerative diseases.  He joined Neuraltus in February of 2010. And please make it a point to check out Eric Valor's Blog by going to http:// friends4eric.blogspot.com

  • 01:02

    Drs Bertram Pitt & Pieter Muntendam - Heart Failure

    in Health

    Today's guests are Drs, Bertram Pitt & Pieter Muntendam two leading heart specialists. 
     
    Bertram Pitt, M.D., F.A.C.C., is a Professor of Medicine Emeritus in the Division of Cardiology at the University of Michigan School of Medicine in Ann Arbor, Michigan.
    Prior to this role, he was the Director of the Division of Cardiology at the University of Michigan School of Medicine. Dr. Pitt has conducted research in many areas of cardiovascular disease, with special emphasis on heart failure and ischemic heart disease.
     Dr. Pitt has published more than 500 articles in peer-reviewed journals and is a member of several professional societies. 
    Pieter Muntendam, M.D., is the Executive Vice President and Chief Medical Officer of BG Medicine. He is a biopharmaceutical and healthcare executive with in-depth business experience ranging from early stage ventures to multinational corporations. Prior to this role, Dr. Muntendam served as President and CEO of BG Medicine from November 2004 through January 2012.
    Dr. Muntendam joined BG Medicine from NetNumina Solutions, Inc., a professional services company, where he served as Director of the Biopharma Healthcare Practice.
    Dr. Muntendam held executive positions with Organon International Inc. and Johnson & Johnson where he was appointed Vice President of Research and Development, International at Johnson & Johnson, and appointed as a member of the boards of directors for two Johnson & Johnson operating companies. Dr. Muntendam received his M.D. from Leiden University in the Netherlands.